Moderna, Inc.’s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Moderna, Inc. (NASDAQ:MRNA) shareholders have had their patience rewarded with a 26% share price jump in the last month. Still, the 30-day jump doesn’t change the fact that longer term shareholders have seen their stock decimated by the 73% share price drop in the last twelve months.
In spite of the firm bounce in price, Moderna may still look like a strong buying opportunity at present with its price-to-sales (or “P/S”) ratio of 3.9x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 8.6x and even P/S higher than 61x aren’t out of the ordinary. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.
